As global markets navigate a volatile start to 2025, with the Federal Reserve holding rates steady and AI competition shaking up the tech sector, investors are closely watching how these dynamics ...

Rising Incidence of Hemophilia, Immunological Disorders, and the Growing Number of Surgical Procedures Worldwide is Driving Growth, at a CAGR of ~9%Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Blood ...

Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR ...

Global in vitro diagnostics (IVD) market will reach $148,393.3 million by 2031, growing by 6.3% annually over 2021-2031. The global in vitro diagnostics (IVD) market encompasses a wide range of ...

Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a collaboration with biotechnology startup FcR Therapeutics to develop recombinant nanobodies ...

For decades, Grifols grew rich from an empire built on blood. Founded by a plucky scientist and his two sons in the years after the Spanish Civil War, the company made a series of breakthroughs that ...

Judge José Luis Calama of the National Court, who is investigating the Grifols case, has asked the National Securities Market Commission ...

Some of Grifols SA ’s board members could be sanctioned for the Spanish drug maker’s accounting deficiencies as the company readies to face off short seller Gotham City Research in a Madrid court.

Regulator says Gotham City attacks could be manipulation CNMV also says short seller right on some accounting issues Drugmaker Grifols SA and US short seller Gotham City Research are counting on two ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.